Multiple Myeloma
2022 Year in Review - Multiple Myeloma | February 17, 2023
Updated phase 2 results of the MonumenTAL-1 study showed promising efficacy and a tolerable safety profile with talquetamab, a novel T-cell–redirecting bispecific antibody, in patients with RRMM.
2022 Year in Review - Multiple Myeloma | February 17, 2023
Real-world analysis of patients with MM determines treatment patterns and survival outcomes in patients with t(11;14) compared to patients with high- and standard-risk cytogenetics.
2022 Year in Review - Multiple Myeloma | February 17, 2023
REGN5458, a BCMAxCD38 bispecific antibody, demonstrated early durable responses with a tolerable safety profile and low rates of CRS in patients with relapsed/refractory multiple myeloma.
2022 Year in Review - Multiple Myeloma | February 17, 2023
Phase 1 data of ALLO-715 followed by lymphodepletion showed durable responses in heavily pretreated RRMM patients.
2022 Year in Review - Multiple Myeloma | February 17, 2023
Data from a subgroup analysis of CANDOR supported the efficacy of daratumumab plus carfilzomib and dexamethasone in RRMM, even in high-risk patients.
2022 Year in Review - Multiple Myeloma | February 17, 2023
Preliminary data support the use of BMS-986393 in patients with RRMM despite prior BCMA-directed therapy.
2022 Year in Review - Multiple Myeloma | February 17, 2023
Updated results from a phase 1 trial of subcutaneous isatuximab via OBDS continue to demonstrate an excellent local tolerability with comparable efficacy.
2022 Year in Review - Multiple Myeloma | February 17, 2023
Implementation of a pharmacist on the healthcare team can have significant clinical and economic benefits.
2022 Year in Review - Multiple Myeloma | February 17, 2023
In the first trial with this treatment regimen, quadruplet induction with Isa-KRd in patients with high-risk MM demonstrated promising activity and a tolerable safety profile.
2022 Year in Review - Multiple Myeloma | February 17, 2023
Novel agent iberdomide demonstrated clinically meaningful activity and was generally well tolerated in a multicohort phase 1/2 trial.